208 related articles for article (PubMed ID: 35893595)
1. Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.
Matsushita H; Misumi Y; Masuda T; Okada M; Inoue F; Ueda M; Ando Y
Pathophysiology; 2022 Jun; 29(3):333-343. PubMed ID: 35893595
[TBL] [Abstract][Full Text] [Related]
2. Transthyretin: Its function and amyloid formation.
Ueda M
Neurochem Int; 2022 May; 155():105313. PubMed ID: 35218869
[TBL] [Abstract][Full Text] [Related]
3. Extracellular Vesicles Contribute to the Metabolism of Transthyretin Amyloid in Hereditary Transthyretin Amyloidosis.
Yamaguchi H; Kawahara H; Kodera N; Kumaki A; Tada Y; Tang Z; Sakai K; Ono K; Yamada M; Hanayama R
Front Mol Biosci; 2022; 9():839917. PubMed ID: 35402512
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen.
Coelho T; Waddington Cruz M; Chao CC; Parman Y; Wixner J; Weiler M; Barroso FA; Dasgupta NR; Jung SW; Schneider E; Viney NJ; Dyck PJB; Ando Y; Gillmore JD; Khella S; Gertz MA; Obici L; Berk JL
Neurol Ther; 2023 Feb; 12(1):267-287. PubMed ID: 36525140
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin Amyloidosis: Update on the Clinical Spectrum, Pathogenesis, and Disease-Modifying Therapies.
Koike H; Katsuno M
Neurol Ther; 2020 Dec; 9(2):317-333. PubMed ID: 32948978
[TBL] [Abstract][Full Text] [Related]
6. A natural history analysis of asymptomatic
Coelho T; Conceição I; Waddington-Cruz M; Keohane D; Sultan MB; Chapman D; Amass L;
Amyloid; 2022 Dec; 29(4):228-236. PubMed ID: 35730447
[TBL] [Abstract][Full Text] [Related]
7. New simple and quick method to analyze serum variant transthyretins: direct MALDI method for the screening of hereditary transthyretin amyloidosis.
Nomura T; Ueda M; Tasaki M; Misumi Y; Masuda T; Inoue Y; Tsuda Y; Okada M; Okazaki T; Kanenawa K; Isoguchi A; Nakamura M; Obayashi K; Shinriki S; Matsui H; Yamashita T; Ando Y
Orphanet J Rare Dis; 2019 May; 14(1):116. PubMed ID: 31133063
[TBL] [Abstract][Full Text] [Related]
8. Drug and Gene Therapy for Treating Variant Transthyretin Amyloidosis (ATTRv) Neuropathy.
Dardiotis E; Kyriakides T
Curr Neuropharmacol; 2023; 21(3):471-481. PubMed ID: 36366846
[TBL] [Abstract][Full Text] [Related]
9. Val50Met hereditary transthyretin amyloidosis: not just a medical problem, but a psychosocial burden.
González-Moreno J; Gaya-Barroso A; Losada-López I; Rodríguez A; Bosch-Rovira T; Ripoll-Vera T; Usón M; Figuerola A; Descals C; Montalà C; Ferrer-Nadal MA; Cisneros-Barroso E
Orphanet J Rare Dis; 2021 Jun; 16(1):266. PubMed ID: 34112225
[TBL] [Abstract][Full Text] [Related]
10. Ultrastructure in Transthyretin Amyloidosis: From Pathophysiology to Therapeutic Insights.
Koike H; Katsuno M
Biomedicines; 2019 Feb; 7(1):. PubMed ID: 30764529
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal analysis of serum neurofilament light chain levels as marker for neuronal damage in hereditary transthyretin amyloidosis.
Berends M; Brunger AF; Bijzet J; Kroesen BJ; Drost G; Lange F; Teunissen CE; In 't Veld S; Vrancken AF; Gans ROB; Hazenberg BPC; van der Zwaag PA; Nienhuis HLA
Amyloid; 2024 Jun; 31(2):132-141. PubMed ID: 38477065
[TBL] [Abstract][Full Text] [Related]
12. A narrative review and expert recommendations on the assessment of the clinical manifestations, follow-up, and management of post-OLT patients with ATTRv amyloidosis.
Casasnovas C; Lladó L; Borrachero C; Pérez-Santamaría PV; Muñoz-Beamud F; Losada-López IA; Baliellas-Comellas MC; González-Moreno J
Ther Adv Neurol Disord; 2023; 16():17562864231191590. PubMed ID: 37655225
[TBL] [Abstract][Full Text] [Related]
13. Plasma growth differentiation factor 15: a novel tool to detect early changes of hereditary transthyretin amyloidosis.
Okada M; Misumi Y; Masuda T; Takashio S; Tasaki M; Matsushita H; Ueda A; Inoue Y; Nomura T; Nakajima M; Yamashita T; Shinriki S; Matsui H; Tsujita K; Ando Y; Ueda M
ESC Heart Fail; 2021 Apr; 8(2):1178-1185. PubMed ID: 33381924
[TBL] [Abstract][Full Text] [Related]
14. Hereditary Transthyretin Amyloidosis- Clinical and Genetic Characteristics of a Multiracial South-East Asian Cohort in Singapore.
Chen Z; Koh JS; Saini M; Tay KSS; Jayne Tan Y; Chai JYH; Fam SR; Juraidah AR; Lim PK; Ng ASL; Prasad K; Tan CB; Umapathi T; Verma KK; Yong MH; Yu C; Ng PS
J Neuromuscul Dis; 2021; 8(4):723-733. PubMed ID: 34024775
[TBL] [Abstract][Full Text] [Related]
15. Sex-Related Risk of Cardiac Involvement in Hereditary Transthyretin Amyloidosis: Insights From THAOS.
Caponetti AG; Rapezzi C; Gagliardi C; Milandri A; Dispenzieri A; Kristen AV; Wixner J; Maurer MS; Garcia-Pavia P; Tournev I; Planté-Bordeneuve V; Chapman D; Amass L;
JACC Heart Fail; 2021 Oct; 9(10):736-746. PubMed ID: 34391735
[TBL] [Abstract][Full Text] [Related]
16. A Narrative Review of the Role of Transthyretin in Health and Disease.
Liz MA; Coelho T; Bellotti V; Fernandez-Arias MI; Mallaina P; Obici L
Neurol Ther; 2020 Dec; 9(2):395-402. PubMed ID: 33001386
[TBL] [Abstract][Full Text] [Related]
17. Cerebellar and Cerebral Amyloid Visualized by [
Uneus EI; Wilhelmsson C; Bäckström D; Anan I; Wixner J; Pilebro B; Riklund K; Ögren M; Ögreen M; Axelsson J; Suhr OB; Sundström T
Front Neurol; 2022; 13():816636. PubMed ID: 35317351
[TBL] [Abstract][Full Text] [Related]
18. Clinical and apparative investigation of large and small nerve fiber impairment in mixed cohort of ATTR-amyloidosis: impact on patient management and new insights in wild-type.
Papagianni A; Ihne S; Zeller D; Morbach C; Üçeyler N; Sommer C
Amyloid; 2022 Mar; 29(1):14-22. PubMed ID: 34632904
[TBL] [Abstract][Full Text] [Related]
19. Serum neurofilament light chain: a promising early diagnostic biomarker for hereditary transthyretin amyloidosis?
Romano A; Primiano G; Antonini G; Ceccanti M; Fenu S; Forcina F; Gentile L; Inghilleri M; Leonardi L; Manganelli F; Obici L; Sabino A; Sciarrone MA; Tozza S; Vitali F; Luigetti M
Eur J Neurol; 2024 Jan; 31(1):e16070. PubMed ID: 37724995
[TBL] [Abstract][Full Text] [Related]
20. Temporal Trends of Wild-Type Transthyretin Amyloid Cardiomyopathy in the Transthyretin Amyloidosis Outcomes Survey.
Nativi-Nicolau J; Siu A; Dispenzieri A; Maurer MS; Rapezzi C; Kristen AV; Garcia-Pavia P; LoRusso S; Waddington-Cruz M; Lairez O; Witteles R; Chapman D; Amass L; Grogan M;
JACC CardioOncol; 2021 Oct; 3(4):537-546. PubMed ID: 34729526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
